Latest Administration News

Page 2 of 248
Racura Oncology has cleared a key ethics hurdle for its pivotal EMILI trial of RC220 in relapsed or refractory acute myeloid leukaemia. The Phase 2b program is funded from existing cash, but efficacy, regulatory and funding tests still stand between the company and Phase 3.
Ada Torres
Ada Torres
18 Nov 2026
Black Bear Minerals has secured MSHA approval for alternative mine rescue arrangements at its Shafter Silver Project in Texas, opening a compliant pathway to underground exploration. The work is intended to support resource validation, a maiden JORC estimate and early mine planning, but exploration has not yet begun.
Maxwell Dee
Maxwell Dee
18 Nov 2026
MA Credit Income Trust has opened a voluntary off-market buy-back for up to 1.25% of its units, giving eligible investors another way to exit at the trust’s net asset value. The final price will be set on 31 December, while acceptances may be scaled back or rejected at the responsible entity’s discretion.
Claire Turing
Claire Turing
17 Nov 2026
Aspermont has told ASX that directors John Stark and Graeme McCracken failed to obtain prior approval or notify the company of transactions, leading to late Appendix 3Y notices. ASX raised possible listing rule and Corporations Act breaches, although no penalty or formal finding has been disclosed.
Victor Sage
Victor Sage
17 Nov 2026
Vitrafy says it has moved from cryopreservation research into commercial execution, with 19 Guardion devices built, new US partnerships and $38.3 million in cash and term deposits. The next test is converting partner evaluations into recurring revenue after a planned FDA Class II listing in the coming weeks.
Victor Sage
Victor Sage
17 Nov 2026
Sandon Capital Investments is promoting a 7.8% fully franked dividend yield and a 7.2% discount to pre-tax NTA, while acknowledging that QPM Energy’s administration cost its portfolio about 7%. The listed investment company says its long-term record and activist holdings continue to offer value, but recent performance has lagged key benchmarks.
Claire Turing
Claire Turing
17 Nov 2026
Island Pharmaceuticals is moving Galidesivir into a decisive sequence of Marburg animal studies after the FDA confirmed an Animal Rule pathway for the antiviral. The company also expects to generate prospective human data through an approved Uganda Ebola program, although approval, funding and commercial outcomes remain unresolved.
Victor Sage
Victor Sage
17 Nov 2026
Epiminder has signed a five-year rolling partnership with Stratus Neuro to integrate its long-term Minder EEG data into StratusEEG, a cloud platform used by more than 7,000 US clinicians and administrators. The agreement gives Epiminder an established clinical workflow for its DETECT study and planned US commercialisation, although no financial terms or launch date were disclosed.
Victor Sage
Victor Sage
17 Nov 2026
New Talisman Gold Mines is seeking up to NZ$3.9 million through a renounceable rights offer to fund drilling, mine infrastructure planning and exploration across its Hauraki Goldfield projects. The raise could double the company’s post-consolidation share count, but the drilling programme will be scaled to the amount raised.
Maxwell Dee
Maxwell Dee
17 Nov 2026
The Supreme Court of Western Australia has approved Genesis Minerals’ proposed acquisition of Vault Minerals, removing a major legal condition to the deal. Vault expects the scheme to become effective on 17 November, with implementation scheduled for 26 November.
Maxwell Dee
Maxwell Dee
16 Nov 2026
Progress 2017-2 Trust’s A$1.012 billion Class A floating rate notes have been redeemed, ending their quotation on ASX. The notes will be suspended on 16 November before the trust is removed from the Official List the following day.
Claire Turing
Claire Turing
16 Nov 2026
Dyno Nobel’s FY26 annual report shows a stronger explosives business emerging from a costly portfolio reshuffle, with EBIT up 17.4% and FY27 guidance set at A$515 million to A$555 million. The trade-off is a heavier balance sheet, a halted buyback and fresh execution risks across gas supply, defence projects and international expansion.
Victor Sage
Victor Sage
16 Nov 2026

Browse the archive

Full archive